We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Next Gen Technology Enables Robust, Straightforward and Flexible Molecular Diagnostics in Any Environment

By LabMedica International staff writers
Posted on 24 Mar 2023
Print article
Image: The novel technology uses fringe-field capacitive sensing to quantify molecular targets (Photo courtesy of AltraTech)
Image: The novel technology uses fringe-field capacitive sensing to quantify molecular targets (Photo courtesy of AltraTech)

The implementation of point-of-care systems is often hindered by challenges related to sample preparation, reagent storage, and user proficiency. Now, a next-generation ‘Anywhere, anytime, by anyone’ molecular detection technology aims to shift the detection and monitoring of viral infections to point-of-care and beyond clinical settings. The technology, which allows for rapid and precise measurement and quantification of viral RNA, DNA, antigens, or antibodies, can be used by anyone, anywhere, at any time.

AltraTech Limited’s (Cork, Ireland) innovative technology integrates nanotechnology, semiconductor technology, and novel PNA chemistry to create a distinct and robust assay. This assay, called Molecular Detection by Proxy, is a bead-based technology that employs ultra-sensitive capacitance detection. The assay involves three critical stages. The first stage uses exclusive bioorthogonal PNAs to overcome the challenge of extracting genetic material from a biological sample without any sample preparation. These synthetic nucleic acids are incredibly specific and can be directly introduced into the sample.

The target is then captured onto a magnetic bead, following which the captured molecules are magnetically removed from the sample and tethered onto coded nanoparticles. These nanoparticles are representative of the biological target, with each particle equivalent to a single target. Finally, the particles are released over a highly sensitive, bioorthogonal CMOS biosensor chip, resulting in a change of capacitance. The higher the number of particles, the greater the measured capacitance, leading to a linear correlation with the initial target present in the sample.

As a result, the assay can be multiplexed with ease and used to measure other targets, including antibodies or antigens, within the same test. Moreover, as soon as a new genome is accessible, the company’s core bioorthogonal PNA chemistry can be promptly programmed with the specific targeting sequences, enabling a new test to be deployed within days. The assay will be integrated into a solid-state device that can be miniaturized, commercialized, and mass-produced.

Related Links:
AltraTech Limited 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.